DNLI

Denali Therapeutics Inc. is a leading biopharmaceutical company focused on advancing innovative therapies for neurodegenerative diseases, addressing significant unmet medical needs. Headquartered in South San Francisco, California, Denali harnesses its proprietary technology platforms to develop disease-modifying treatments that target the underlying biology of various neurological disorders. The company's pipeline includes promising candidates that leverage its expertise in transport biology and neuroinflammatory processes, strategically positioning it as a key player in the neurotherapeutics space. Through robust clinical programs and strategic collaborations, Denali aims to improve outcomes for patients suffering from debilitating conditions such as Alzheimer’s and Parkinson’s diseases.